Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 14 May 20 424B3 Prospectus supplement
- 10 Apr 20 EFFECT Notice of effectiveness
- 9 Apr 20 424B3 Prospectus supplement
- 6 Apr 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 6 Apr 20 S-4/A Registration of securities issued in business combination transactions (amended)
-
27 Mar 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 13 Mar 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 4 Feb 20 S-4 Registration of securities issued in business combination transactions
QLGN similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Auditor
We consent to the use in this Amendment No. 2 to the Registration Statement (No.333-236235) on Form S-4 of Ritter Pharmaceuticals Inc. of our report dated March 5, 2020, relating to the financial statements of Qualigen, Inc. (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the Company’s ability to continue as a going concern), appearing in this Registration Statement on Form S-4.
We also consent to the reference to our firm under the heading “Experts” in such Registration Statement.
/s/ SQUAR MILNER LLP
San Diego, CA
March 27, 2020